UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Jetstar to Charge for Overhead Cabin Bags From February 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
NEW DELHI, India, March 12, 2018 -- Vyome Biosciences, a clinical-stage specialty pharmaceutical company developing novel medicines for treating skin diseases caused by resistant microbes, today announces that N. Venkat, chief executive officer and co-founder of Vyome Biosciences, will present at the Cowen and Company 38th Annual Health Care Conference at 11:30 a.m. EDT on Tuesday, March 13, 2018, at the Boston Marriott Copley Plaza, Boston.
About Vyome Biosciences
Vyome Biosciences is an innovation-driven, clinical stage bio-pharmaceutical company, which has novel platforms technologies and a deep pipeline of novel drugs for antibiotic resistant acne, and other opportunistic skin pathogens. The company’s lead drug candidate, VB 1953, is a topical treatment product candidate for antibiotic resistant acne being studied in phase 2 trials. Vyome has a deep pipeline of preclinical new chemical entities, which are unique in their ability to overcome the development of resistance and are based on its patented Dual Action Rational Therapeutics (DARTs) technology. Vyome has developed clinically proven antifungal products based on innovative and patented technology platform Molecular Replacement Therapeutics (MRT™). Vyome has assembled a world-class team of scientific and business development experts who have a track record of conducting scientific research, developing breakthrough products and building sustainable businesses. More information is available at http://www.vyome.in and @VyomeBio.
Media contact:
Josephine Belluardo, Ph.D.
LifeSci Public Relations
(646) 751-4361
[email protected]
